Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Starting soon · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure

In brief

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Key facts

Study ID

NCT06866236

Run by

Ebima Clifford Okundaye

People needed

3000

Starts

2025-10-01

Expected to finish

2027-07-01

Last updated by the study team

2025-09-08

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion criteria
• Patient with Chronic kidney disease
• Estimated Glomerular function by MDRD of less than 60mls/min
• Patients with declining renal function ( as measured by eGFR by MDRD )
• Rate of decline of eGFR over the last one year of less than 20%
• Negative Serology markers for CKD etiology
• Provider perceived adherence to study follow up

You may not qualify if…

• Rapid rate of decline in kidney function of > 20 % over last one year
• Symptomatic renal failure
• Presence of any suspected Acute renal failure superimposed
• Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
• No known reversible cause of renal decline

Where it is running

• Neukidney Inc — Pasedena, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.